Reduction of Activin A gives rise to comparable expression of key definitive endoderm and mature beta cell markers
CET human iPS cells were cited in a recent issue of Regenerative Medicine evaluating methods to differentiate human stem cells into insulin-producing cells.
CET provides researchers with high-performing and scalable iPS cell lines and lowering the cost of therapeutic development with their high-performing, low-cost growth factors.
Click here to read the full article.
Reach out to any of our Sciencewerke sales representatives at [email protected] or call us at: 6777 1045 to learn how the CD34+ and Multipotent iPSCs can accelerate your research and development efforts.